Prevalence of sarcopenia in elderly maintenance hemodialysis patients: The impact of different diagnostic criteria

Lamarca, Fernando; Carrero, Juan Jesús; Rodrigues, Juliana; Bigogno, Fernanda Guedes; Fetter, Renata; Avesani, Carla María

doi:10.1007/s12603-014-0505-5

Cited by 126 publications

(92 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the prevalence of sarcopenia by MAMC (9.8%) and BIA (5.9%) evidenced here was similar to that of other studies that used the same methods, such as Gariballa et al by using MAMC in hospitalized patients [38] and Volpato et al by using BIA in institutionalized elderly [18]. In elderly hemodialysis patients, Lamarca et al also found a lower prevalence of sarcopenia when using BIA in comparison with MAMC (respectively 13 versus 31%) both in association with reduced HGS [25]. However, when using an unconventional definition for low muscle mass by BIA (<20th percentile of health individuals), the prevalence rose up to 45%, highlighting the importance of cutoffs adopted when interpreting the prevalence of sarcopenia.…”

Section: O R I G I N a L A R T I C L Esupporting

confidence: 89%

See 1 more Smart Citation

Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality

Pereira

Cordeiro

Avesani

et al. 2015

Nephrol. Dial. Transplant.

271

221

View full text Add to dashboard Cite

Correspondence and offprint requests to: Maria Ayako Kamimura: E-mail: m.kamimura@uol.com.br A B S T R AC TBackground. In chronic kidney disease (CKD), multiple metabolic and nutritional abnormalities contribute to the impairment of skeletal muscle mass and function thus predisposing patients to the condition of sarcopenia. Herein, we investigated the prevalence and mortality predictive power of sarcopenia, defined by three different methods, in non-dialysis-dependent (NDD) CKD patients. Methods. We evaluated 287 NDD-CKD patients in stages 3-5 [59.9 ± 10.5 years; 62% men; 49% diabetics; glomerular filtration rate (GFR) 25.0 ± 15.8 mL/min/1.73 m 2 ]. Sarcopenia was defined as reduced muscle function assessed by handgrip strength (HGS <30th percentile of a population-based reference adjusted for sex and age) plus diminished muscle mass assessed by three different methods: (i) midarm muscle circumference (MAMC) <90% of reference value (A), (ii) muscle wasting by subjective global assessment (B) and (iii) reduced skeletal muscle mass index (<10.76 kg/m² men; <6.76 kg/m² women) estimated by bioelectrical impedance analysis (BIA) (C). Patients were followed for up to 40 months for all-cause mortality, and there was no loss of follow-up.

show abstract

Section: O R I G I N a L A R T I C L Esupporting

confidence: 89%

“…However, studies are still scarce in this population, and they are limited to elderly hemodialysis patients [24,25]. Herein, we aimed to evaluate the prevalence and prognostic power of sarcopenia, assessed by three different criteria, in non-dialysis-dependent (NDD) CKD patients followed up to 40 months.…”

mentioning

confidence: 99%

Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality

Pereira

Cordeiro

Avesani

et al. 2015

Nephrol. Dial. Transplant.

271

221

View full text Add to dashboard Cite

show abstract

“…Sarcopenia may be more severe among vulnerable populations, such as those with end-stage renal disease. In hemodialysis patients, the prevalence of sarcopenia was reported to be between 12.7% and 33.7% [4][5][6], and those with sarcopenia have an increased risk of fractures, anxiety, depression, cardiovascular complications, and mortality [4,[7][8][9]. Therefore, early identification and interventions for hemodialysis patients with sarcopenia are essential for effective disease management.…”

Section: Introductionmentioning

confidence: 99%

SARC‐F Questionnaire: Rapid and Easy Tool for Identifying Physical Limitations in Hemodialysis Patients

Yamamoto

Matsuzawa

Harada

et al. 2019

JCSM Clinical Reports

View full text Add to dashboard Cite

Background SARC-F is a simple questionnaire for rapidly assessing physical function and screening for sarcopenia. This study aimed to determine whether the SARC-F questionnaire is useful for identifying impaired physical function and the risk of physical limitations in hemodialysis patients. Methods and resultsThis cross-sectional study included 281 patients undergoing hemodialysis at two dialysis units. SARC-F, handgrip strength, leg strength, one-leg standing time, usual gait speed, and short physical performance battery (SPPB) score were measured. Patients were classified according to the SARC-F score (SARC-F <4 and SARC-F ≥4), indicating the risk of sarcopenia. Furthermore, we defined physical limitations as handgrip strength of <26 kg for men and <18 kg for women, leg strength of <40%, usual gait speed of ≤0.8 m/s, and SPPB score of ≤8 points. To calculate the areas under the curves (AUCs) of the SARC-F score for physical limitations, receiver-operating characteristic curve analysis was performed. SARC-F ≥4 was observed in 75 (26.7 %) hemodialysis patients. The SARC-F ≥4 group had a significantly lower handgrip and leg strength, shorter one-leg standing time, slower usual gait speed, and lower SPPB score than the SARC-F <4 group, even after adjusting for potential confounders (all P <0.001). Further, SARC-F demonstrated good accuracy in identifying the risk of physical limitations (all AUCs > 0.75). Conclusions The SARC-F questionnaire is useful for screening impaired physical function and for identifying the risk of physical limitations in hemodialysis patients and can be easily and rapidly administered to this patient group in clinical practice.

show abstract

“…The choices of cutoffs and reference populations are not inconsequential, because the prevalence of sarcopenic obesity in adults in the NHANES varied up to 26-fold depending on the many research definitions available in the literature (21), reflecting overall a profound lack of agreement among scientific societies. Our own attempts to accurately classify sarcopenia in patients on dialysis yielded a similar wide variability (22). There is certainly a need to establish consensus criteria that can be reliably applied across clinical and research settings.…”

mentioning

confidence: 99%

Misclassification of Obesity in CKD

Carrero¹

2014

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Prevalence of sarcopenia in elderly maintenance hemodialysis patients: The impact of different diagnostic criteria

Abstract: A wide prevalence of sarcopenia is observed depending on the method and cutoff limit applied. This may limit extrapolate on to clinical practice. BIA and SKF were the surrogate methods to assess muscle mass with the best concordance with DXA in elderly MHD patients.

Cited by 126 publications

References 30 publications

Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality

Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality

SARC‐F Questionnaire: Rapid and Easy Tool for Identifying Physical Limitations in Hemodialysis Patients

Misclassification of Obesity in CKD

Contact Info

Product

Resources

About